Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.66 USD

12.66
254,121

+0.02 (0.16%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $12.68 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

by Zacks Equity Research

Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

    Zacks Equity Research

    Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why

    by Zacks Equity Research

    Let us look at the factors that have led to the increase in share price of Emergent (EBS).

      Zacks Equity Research

      Novo Nordisk Obtains Licence for Sickle Cell Disease Program

      by Zacks Equity Research

      Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

        Zacks Equity Research

        Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session

        by Zacks Equity Research

        Shares of Rigel Pharmaceuticals (RIGL) rose over 8% yesterday.

          Zacks Equity Research

          Bio-Path Leukemia Combo Study Shows Positive Early Data

          by Zacks Equity Research

          Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

            Zacks Equity Research

            Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU

            by Zacks Equity Research

            Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.

              Zacks Equity Research

              Alkermes Sinks as FDA Refuses Depression Drug Review

              by Zacks Equity Research

              Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).

                Zacks Equity Research

                Edge Therapeutics Loses Edge on Failure of Late-Stage Study

                by Zacks Equity Research

                Edge Therapeutics (EDGE) plummeted significantly after the company announced discontinuation of the pivotal late stage study on lead candidate.

                  Zacks Equity Research

                  Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?

                  by Zacks Equity Research

                  Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.

                    Zacks Equity Research

                    Novo Nordisk Poised on Strong Pipeline Amid Competition

                    by Zacks Equity Research

                    Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.